Lipedema: A Disease Seen, Forgotten, Named – and Slowly Understood
Lipedema did not suddenly appear in 1940. It was seen long before it was named. For more than a century, women carried the symptoms while medicine struggled to classify what it was looking at. The history of lipedema is not only the history of a disease. It is the history of recognition.
1830s: Observed but Misunderstood
In the 1830s, the French physician Pierre-François Olive Rayer described women with symmetrical swelling and fatty enlargement of the lower limbs in his medical writings. The condition was interpreted as a vascular or renal disorder and labeled within categories such as phlegmasia alba dolens.
Later in the 19th century, physicians like Erasmus Wilson described painful fatty legs in women after puberty. These cases were framed as obesity variants, constitutional weakness, or even nervous disorders.
The symptoms were there: symmetry, pain, bruising, resistance to dieting.
But there was no framework to hold them together.
Medicine at the time was focused on infections, surgery, and emerging bacteriology. Women’s chronic body complaints were often minimized or psychologized. Without histology, endocrinology, or standardized classification systems, lipedema-like cases remained scattered anecdotes.
Seen. Not defined.
1920s: The First Structured Descriptions
In Germany during the 1920s, physicians began describing what they called constitutional lipomatosis. F. von Buerger published work in 1922 describing hypertrophic fat accumulation in women, often triggered by puberty or pregnancy.
Other clinicians referred to “dicker Beine” – thick legs that did not respond to weight loss and were often painful. Hormonal influence and family history were noted.
This marked an important shift. The condition was no longer purely cosmetic. It was being considered pathological. Yet it still lacked a distinct name and formal classification.
Recognized. But not separated.
1940: A New Clinical Entity
In 1940, Edgar Van Nuys Allen and Edwin Hines Jr. at Mayo Clinic published “Lipedema: A New Clinical Entity?”
For the first time, the condition was formally defined and named.
They described:
Symmetrical, painful fat accumulation
Orthostatic edema
Sparing of hands and feet
Resistance to dieting
They emphasized that it was neither obesity nor lymphedema. They proposed hormonal triggers and genetic predisposition.
The core clinical picture we still use today was already there.
Named. Clearly separated.
But still rare in the literature.
1970s–2000s: European Focus, Limited Global Awareness
In Germany, the term “Lipoedema” became more widely used in the 1970s. Conservative treatment approaches such as compression therapy and complex decongestive therapy were implemented. Liposuction techniques were gradually introduced, particularly tumescent methods.
Yet globally, lipedema remained under-recognized. It was frequently misdiagnosed as obesity or secondary lymphedema. There were no biomarkers, no large cohorts, and no standardized guidelines.
It existed in specialty clinics, not mainstream medicine.
2012: When I Was Diagnosed
When I received my diagnosis in 2012, the knowledge base was still limited and fragmented.
Diagnosis was entirely clinical. The criteria described by Allen and Hines in 1940 were still the foundation. There were no blood tests, no validated imaging markers, no molecular explanation.
If you enjoy the content on LipedemaScience, support the author CarinaW by sharing the article with a lipedema sister.
The condition was described as:
A chronic, symmetrical fat disorder
Painful and resistant to dieting
Triggered by hormonal life stages
Possibly genetic
Prevalence was often estimated at 10–11 percent of women, but this was based on clinical impressions rather than robust epidemiology. Underdiagnosis was acknowledged but not quantified.
Pathophysiology was largely unknown. Histology showed hypertrophic adipocytes and interstitial fluid. Inflammation and fibrosis were mentioned but not mechanistically understood.
Treatment in 2012 was conservative:
Compression garments
Manual lymphatic drainage
Lifestyle advice
Liposuction was performed in specialized centers, especially in Germany, but remained controversial due to lack of randomized controlled trials. There were no pharmacological options. No disease-modifying therapy.
In 2012, lipedema was recognized.
But it was not biologically explained.
2015–2026: From Description to Molecular Insight
The past decade has marked a shift.
Research has moved into molecular territory. Small but significant studies have identified:
Differential gene expression linked to adipogenesis and inflammation
MicroRNA profiles specific to lipedema tissue
Metabolomic signatures distinguishing lipedema from obesity
Evidence of endothelial dysfunction and increased vascular permeability in early stages
Early-stage fibrosis and extracellular matrix remodeling
The narrative has changed.
Lipedema is no longer described as “just fat.” It is increasingly understood as a complex interaction between adipose tissue dysfunction, microvascular alterations, inflammation, and possibly genetic susceptibility.
Yet the field is still young.
Most studies involve small cohorts. Biomarkers are not yet validated for clinical use. Large longitudinal studies are still lacking. There is no definitive blood test.
Recognition has improved, especially after lipedema was included in ICD-11 by the World Health Organization in 2018. But access to diagnosis and treatment still varies widely between countries.
Today: Recognized – But Not Fully Understood
We now speak about endothelial permeability, macrophage infiltration, extracellular matrix remodeling, and gene expression patterns. These were unimaginable concepts in 1940.
Compared to 2012, the scientific depth has expanded dramatically. Compared to where it needs to be, we are still early.
Lipedema’s history shows a recurring pattern:
Observed
Minimized
Named
Underestimated
Rediscovered
Investigated
The disease has always been there. What changed is the framework through which medicine interprets it.
And perhaps the most important shift is this: women are no longer silent data points. They are part of driving the research forward.
The story of lipedema is still being written.